{"id":"bromfenac-0-09-ophthalmic-solution","safety":{"commonSideEffects":[{"rate":null,"effect":"Ocular irritation or stinging"},{"rate":null,"effect":"Conjunctival hyperemia"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Corneal adverse events (rare)"}]},"_chembl":null,"_dailymed":{"setId":"225070ee-d862-4d41-84b8-5bd7a8a03fd7","title":"BROMFENAC OPHTHALMIC SOLUTION 0.09% SOLUTION/ DROPS [ALEMBIC PHARMACEUTICALS INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By blocking COX-1 and COX-2 enzymes, bromfenac decreases production of inflammatory prostaglandins in ocular tissues. This reduces inflammation, pain, and photophobia associated with ocular surgery and other inflammatory conditions of the eye. The ophthalmic solution formulation allows direct delivery to the anterior segment.","oneSentence":"Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis in the eye.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:28:17.048Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Postoperative inflammation and pain following ocular surgery"},{"name":"Reduction of ocular inflammation and pain in patients undergoing cataract surgery"}]},"trialDetails":[{"nctId":"NCT07178639","phase":"NA","title":"Comparing Efficacy of Bromfenac 0.09%, Nepafenac 0.3% and Diclofenac 0.1% in Patients After Cataract Surgery","status":"RECRUITING","sponsor":"Nemocnice Kolín","startDate":"2025-08-01","conditions":"Macular Oedema, Cataract Surgery, NSAID (Non-Steroidal Anti-Inflammatory Drug)","enrollment":150},{"nctId":"NCT03317847","phase":"PHASE4","title":"Bromfenac Versus Dexamethasone After Cataract Surgery","status":"COMPLETED","sponsor":"Azienda USL Reggio Emilia - IRCCS","startDate":"2017-10-16","conditions":"Inflammation Eye","enrollment":92},{"nctId":"NCT02137161","phase":"PHASE4","title":"Bromfenac to Reduce Inflammation in Patients With Pseudoexfoliation Syndrome After Cataract Surgery","status":"COMPLETED","sponsor":"Azienda USL Reggio Emilia - IRCCS","startDate":"2013-11","conditions":"Cataract, Pseudoexfoliation Syndrome","enrollment":62},{"nctId":"NCT06785090","phase":"PHASE4","title":"Effects of Bromfenac on Macular Thickness After Phacoemulsification Surgery","status":"COMPLETED","sponsor":"Inas Abd","startDate":"2023-05-01","conditions":"Cataract, Cystoid Macular Edema After Phacoemulsification","enrollment":87},{"nctId":"NCT05158699","phase":"PHASE3","title":"Effectiveness of Periocular Drug Injection in CATaract Surgery","status":"TERMINATED","sponsor":"Luigi Rondas","startDate":"2021-10-13","conditions":"Macular Edema, Cystoid Macular Edema, Retinal Disease","enrollment":628},{"nctId":"NCT06130384","phase":"PHASE4","title":"Pain Reduction With Topical Bromfenac Versus Artificial Tear After Intravitreal Injection.","status":"COMPLETED","sponsor":"Wills Eye","startDate":"2021-03-01","conditions":"Pain, Intravitreal Injection, Pain, Acute","enrollment":97},{"nctId":"NCT04343222","phase":"PHASE4","title":"Control of Pain in Intravitreal Injections Using Topical NSAIDs","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2019-06-27","conditions":"Intravitreal Injections, IVI","enrollment":46},{"nctId":"NCT05715385","phase":"PHASE4","title":"Comparison of Treatments in Diabetic Macular Edema","status":"COMPLETED","sponsor":"Babasaheb Ambedkar Memorial Hospital","startDate":"2014-11","conditions":"Diabetic Macular Edema","enrollment":60},{"nctId":"NCT04940338","phase":"PHASE4","title":"PCME Prevention in Patients With NPDR","status":"COMPLETED","sponsor":"Klinički Bolnički Centar Zagreb","startDate":"2021-05-01","conditions":"Cystoid Macular Edema Following Cataract Surgery","enrollment":90},{"nctId":"NCT01310127","phase":"PHASE4","title":"Clinical Outcomes of Bromday (Bromfenac Ophthalmic Solution) 0.09% QD vs. Nevanac (Nepafenac Ophthalmic Suspension) 0.1%","status":"COMPLETED","sponsor":"Toyos Clinic","startDate":"2010-11","conditions":"Inflammation, Pseudophakia","enrollment":23},{"nctId":"NCT01535443","phase":"PHASE1","title":"Safety and Tolerability of PRO-155 Ophthalmic Solution 0.09% in Healthy Volunteers.","status":"COMPLETED","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2011-09","conditions":"Inflammation, Cataract","enrollment":35},{"nctId":"NCT01657266","phase":"PHASE2","title":"Efficacy and Safety of PRO-155 Versus Nevanac in Post Phacoemulsification","status":"COMPLETED","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2013-12","conditions":"Cataract, Phacoemulsification Cataract Surgery","enrollment":160},{"nctId":"NCT03597867","phase":"PHASE3","title":"PGE2 Levels in Patient Treated With NSAIDs","status":"COMPLETED","sponsor":"University of Trieste","startDate":"2018-04-25","conditions":"Ocular Inflammation","enrollment":104},{"nctId":"NCT01774474","phase":"PHASE3","title":"PRevention of Macular EDema After Cataract Surgery","status":"COMPLETED","sponsor":"Maastricht University Medical Center","startDate":"2013-07-10","conditions":"Cystoid Macular Edema, Cataract, Diabetes Mellitus","enrollment":1127},{"nctId":"NCT00438243","phase":"PHASE2","title":"Pilot Study of the Effect of Topical Bromfenac Ophthalmic Solution 0.09%in Patients With Acute Post-operative Cystoid Macular Edema.","status":"WITHDRAWN","sponsor":"Johns Hopkins University","startDate":"2008-05","conditions":"Cystoid Macular Edema","enrollment":""},{"nctId":"NCT01475877","phase":"","title":"Bromday Versus Nevanac Eye Drops to Control Pain Following Photorefractive Keratectomy","status":"COMPLETED","sponsor":"Virdi Eye Clinic","startDate":"2011-05","conditions":"Myopia","enrollment":20},{"nctId":"NCT00703781","phase":"PHASE3","title":"Efficacy and Safety of Bromfenac Ophthalmic Solution in Cataract Surgery","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2008-06","conditions":"Cataract","enrollment":126},{"nctId":"NCT02361645","phase":"PHASE3","title":"NSAIDs and PGE2 Levels in Vitrectomy Patients","status":"COMPLETED","sponsor":"Università degli Studi di Brescia","startDate":"2014-03","conditions":"Vitreous Inflammation","enrollment":70},{"nctId":"NCT00585975","phase":"PHASE2","title":"Efficacy and Safety of Bromfenac Ophthalmic Solution","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2007-10","conditions":"Cataract Surgery","enrollment":568},{"nctId":"NCT00853970","phase":"PHASE3","title":"Efficacy Study of Bromfenac Ophthalmic Solution in Patients Undergoing Cataract Surgery","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2009-02","conditions":"Pain, Inflammation","enrollment":299},{"nctId":"NCT00704418","phase":"PHASE3","title":"Efficacy and Safety of Bromfenac Ophthalmic Solution in Cataract Surgery","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2008-06","conditions":"Cataract","enrollment":156},{"nctId":"NCT00828477","phase":"PHASE4","title":"Evaluation of Comfort With Xibrom (Bromfenac Ophthalmic Solution)0.09% and Nevanac (Nepafenac Ophthalmic Suspension) 0.1% Following Selective Laser Trabeculoplasty (SLT)","status":"COMPLETED","sponsor":"Bp Consulting, Inc","startDate":"2009-01","conditions":"Intraocular Pressure","enrollment":25},{"nctId":"NCT00491166","phase":"PHASE1","title":"Safety Study of Bromfenac Ophthalmic Solution in Subjects With Diffuse Diabetic Macular Edema (DME) Refractory to Laser","status":"UNKNOWN","sponsor":"Ophthalmic Consultants of Boston","startDate":"2007-06","conditions":"Diabetic Macular Edema","enrollment":10}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Yellox","Bromfenac 0.09 %"],"phase":"marketed","status":"active","brandName":"Bromfenac 0.09 % Ophthalmic Solution","genericName":"Bromfenac 0.09 % Ophthalmic Solution","companyName":"Azienda USL Reggio Emilia - IRCCS","companyId":"azienda-usl-reggio-emilia-irccs","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis in the eye. Used for Postoperative inflammation and pain following ocular surgery, Reduction of ocular inflammation and pain in patients undergoing cataract surgery.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}